期刊
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY
卷 -, 期 -, 页码 -出版社
WILEY
DOI: 10.1002/psp4.13060
关键词
-
Conditionally activated molecules, such as Probody therapeutics, are investigated for their potential to improve antitumoral response while reducing systemic toxicity. This study used a quantitative systems pharmacology model to evaluate the effectiveness and targeting specificity of an anti-PD-L1 Probody therapeutic compared to the non-modified antibody. The results suggest that optimizing the design parameters of the Probody therapeutic can increase its efficacy.
Conditionally activated molecules, such as Probody therapeutics (PbTx), have recently been investigated to improve antitumoral response while reducing systemic toxicity. PbTx are engineered to be proteolytically activated by proteases that are preferentially active locally in the tumor microenvironment (TME). Here, we perform an exploratory study using our recently published quantitative systems pharmacology model, previously validated for other drugs, to evaluate the effectiveness and targeting specificity of an anti-PD-L1 PbTx compared to the non-modified antibody. We have informed the model using the PbTx dynamics and pharmacokinetics published in the literature for anti-PD-L1 in patients with triple-negative breast cancer (TNBC). Our results suggest masking of the antibody slightly decreases its efficacy, while increasing the localization of active therapeutic component in the TME. We also perform a parameter optimization for the PbTx design and drug dosing regimens to maximize the response rate. Although our results are specific to the case of TNBC, our findings are generalizable to any conditionally activated PbTx molecule in solid tumors and suggest that design of a highly effective and selective PbTx is feasible.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据